3 weeks ago
IIT Bombay Study Reveals Why Deadly Brain Cancer Returns
A very dangerous brain cancer called glioblastoma usually comes back after treatment, and when it returns it is even harder to treat.
Scientists at IIT Bombay wanted to find out why this happens.
They discovered that the softness of the brain matters a lot for how the cancer behaves.
For a long time, scientists studied cancer cells on hard plastic dishes, which does not match the real brain.
On those hard dishes, returning cancer cells looked the same as the first cancer cells, so scientists could not see what made them different.
But when the same cells were grown on soft gels that feel like brain tissue, they became more aggressive and moved around more, just like in patients.
The scientists also found a special protein called PLEKHA7 that only showed up when cells grew on soft gels and was higher in patients whose cancer had returned.
When they blocked this protein, the tumours grew and spread much less.
They also found that a molecule called NEAT1 helped cancer act more aggressively in a soft brain-like environment, and lowering its levels slowed the cancer.
This shows that testing cancer drugs in brain-like soft gels could help scientists create better treatments.
An IIT Bombay-led study found that the softness of brain tissue, not just genetic changes, makes recurring glioblastoma tumours more aggressive.
The research challenges the common practice of studying cancer cells on rigid plastic laboratory dishes.
Radiation-surviving glioblastoma cells formed more aggressive tumours in mice brains and became more invasive when grown on brain-like soft hydrogels.
The team identified the protein PLEKHA7, found at higher levels in recurrent patient tumours, and blocking it significantly reduced tumour growth and spread.
The gene-regulating RNA molecule NEAT1 became highly active in soft brain-like environments, and reducing its levels slowed tumour growth and made tumoroids less invasive.
- Who
- Researchers at IIT Bombay led by Prof. Abhijit Majumder, in collaboration with researchers from ACTREC and Tata Memorial Centre, with Prof. Shilpee Dutt also collaborating.
- What
- Identified that brain tissue softness makes recurrent glioblastoma tumours more aggressive and revealed new drug targets including the protein PLEKHA7 and the RNA molecule NEAT1.
- Where
- Mumbai, India, at the Indian Institute of Technology (IIT) Bombay.
- When
- No specific date is reported in the articles; the study was published in the journal Matrix Biology.
- Why
- To understand why glioblastoma almost always returns after treatment and to improve cancer drug discovery, which currently sees nearly 90% of promising drugs fail in human clinical trials.
Key facts
- Cancer type
- Glioblastoma
- Lead researcher
- Prof. Abhijit Majumder, IIT Bombay
- Collaborating institution
- ACTREC, Tata Memorial Centre
- Study journal
- Matrix Biology
- Key finding
- Brain tissue softness drives aggressiveness of recurrent tumours
- Biomarkers identified
- Protein PLEKHA7 and RNA molecule NEAT1
- Patient survival after diagnosis
- Six months to one year
- Cancer drug failure rate in clinical trials
- Nearly 90%
Quotes
Prof. Abhijit Majumder
Lead investigator of the IIT Bombay glioblastoma study
“The rigid surface didn't just suppress the cells' aggressive behaviour; it completely erased the distinction between primary and recurrent tumour cells.”
freepressjournal.in
“If someone has a cancer drug target, they should include soft gels and tumoroids as an initial experiment.”
freepressjournal.in






